U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C9H11FN2O5
Molecular Weight 246.1924
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL

SMILES

OC[C@H]1O[C@H]([C@@H](F)[C@@H]1O)N2C=CC(=O)NC2=O

InChI

InChIKey=UIYWFOZZIZEEKJ-PXBUCIJWSA-N
InChI=1S/C9H11FN2O5/c10-6-7(15)4(3-13)17-8(6)12-2-1-5(14)11-9(12)16/h1-2,4,6-8,13,15H,3H2,(H,11,14,16)/t4-,6+,7-,8-/m1/s1

HIDE SMILES / InChI

Molecular Formula C9H11FN2O5
Molecular Weight 246.1924
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

1-(2-DEOXY-2-FLUORO-β-D-ARABINOFURANOSYL)URACIL (FAU) is a thymidine analog. In several cancer cell lines, FAU was phosphorylated intracellularly to its monophosphate, 1-(2-deoxy-2-fluoro--Darabinofuranosyl) uracil monophosphate (FAUMP), by thymidine kinase and methylated in the 5-position by thymidylate synthase to form the product, 1-(2-deoxy-2-fluoro- -D-arabinofuranosyl) 5-methyluracil monophosphate (FMAUMP). FAU strongly inhibits the growth of tumor cells with high thymidylate synthase activity. FAU had been in phase I clinical trial for the treatment of advanced solid tumors.

CNS Activity

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
2.1 ng/mL
50 mg/m² single, intravenous
FMAU plasma
Homo sapiens
1479 ng/mL
50 mg/m² single, intravenous
1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL plasma
Homo sapiens
1152 ng/mL
50 mg/m² 1 times / week multiple, intravenous
1-(2-DEOXY-2-FLUORO-.BETA.-D-ARABINOFURANOSYL)URACIL plasma
Homo sapiens
4.1 ng/mL
50 mg/m² 1 times / week multiple, intravenous
FMAU plasma
Homo sapiens

PubMed

Sample Use Guides

In Vivo Use Guide
Mice: In 25% ethanol 5 ul/g (0.74 mg/kg (0.16 uCi/g))
Route of Administration: Intravenous
In Vitro Use Guide
Coincubation of [3H]-FAU (43 nM/l) in vitro with 50 nmol/L FdUrd decreased FAU incorporation into DNA by 70% in HT29 and 84% in LS174T.
Substance Class Chemical
Record UNII
K7386OMP29
Record Status Validated (UNII)
Record Version